Characterizing disease and treatment response in colon cancer chemoprevention

结肠癌化学预防中的疾病特征和治疗反应

• 批准号: 8054955
• 负责人: Monica M Bertagnolli
• 金额: $ 16.3万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8054955
• 关键词: Address; Adenocarcinoma; Alcohol consumption; Aspirin; Award; Biology; Blood specimen; Body mass index; Cancer Center; Cardiovascular system; Categories; Cells; Cessation of life; Chemistry; Chemoprevention; Chemopreventive Agent; Clinical Data; Clinical Trials; Cohort Studies; Colon Carcinoma; Colonoscopy; Colorectal; Colorectal Adenoma; Colorectal Cancer; Colorectal Neoplasms; Complex; Congestive Heart Failure; Critiques; Data; Data Collection; Development; Diet; Dietary Assessment; Disease; Disease Progression; Drug user; Estrogen Receptors; Event; Faculty; Future; Genomics; Histology; Hormonal; Human; Individual; Inflammatory; K-Series Research Career Programs; Laboratory Study; Lead; Measures; Medical History; Mentors; Myocardial Infarction; Nature; Non-Steroidal Anti-Inflammatory Agents; Obesity; Participant; Patients; Pharmaceutical Preparations; Placebos; Premalignant; Prevention; Prevention Research; Preventive; Principal Investigator; Process; Questionnaires; Randomized; Recurrence; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Risk; Risk Factors; Safety; Screening procedure; Serum; Specimen; Stroke; Testing; Time; Tissues; Tobacco use; Toxic effect; Training; Translational Research; Variant; Work; adenoma; cancer chemoprevention; cancer prevention; cardiovascular risk factor; celecoxib; clinically relevant; colorectal cancer prevention; design; disorder risk; experience; high risk; member; multidisciplinary; programs; prospective; randomized placebo controlled trial; receptor expression; response; skills; tissue resource; tool; treatment response; tumor; tumorigenesis

Colorectal cancer (CRC) is a preventable disease, but still claims many lives because we have yet to optimally implement preventive therapies. One of the biggest challenges is the fact that CRC is not a single uniform disease, but rather a complex multifactoral process with variable expression in susceptible individuals. Developing safe and effective chemoprevention for CRC requires understanding the nature of early colorectal tumorigenesis in actual patients at risk for this disease and following through to test new mechanistically valid chemopreventive agents in human clinical trials. Few research centers have the experienced investigators, resources, and supportive infrastructure required for successful completion of cancer chemoprevention trials. As a result, there is a great need to train new investigators to conduct this important research. Dr. Monica Bertagnolli is an experienced translational researcher in colorectal cancer (CRC) prevention. She is the Lead Principal Investigator of the recently completed Adenoma Prevention with Celecoxib (APC) Trial, a randomized placebo-controlled study of more than 2000 patients at high risk for CRC. She also directs a laboratory studying the biology of pre-malignant adenomas and the tissue-specific effects of chemopreventive compounds. This proposal for an established investigator career development award outlines a plan for Dr. Bertagnolli to spend a significant amount of time over the next 5 years mentoring junior faculty members in cancer prevention research. She will use the considerable clinical data and tissue resources of the APC Trial to provide advisees with the raw materials necessary to conduct studies of modifiable factors in CRC development and chemopreventive drug response. She also establish a multidisciplinary forum for presentation, discussion, and critique of ongoing work in Gl cancer prevention, aided by senior Dana Farber-Harvard Cancer Center investigators and outside consultants. Conducting high quality translational research in a manner that optimizes educational potential is extremely time consuming, and Dr. Bertagnolli is one of the few individuals who can succeed in this task. The support provided by this award will allow Dr. Bertagnolli to complete key research projects using APC Trial resources in a manner that facilitates maturation of junior faculty into independent researchers in cancer prevention.

结直肠癌 (CRC) 是一种可预防的疾病，但由于我们尚未最佳地实施预防性治疗，它仍然夺去了许多人的生命。最大的挑战之一是结直肠癌不是一种单一的统一疾病，而是一个复杂的多因素过程，易感个体的表达存在差异。开发安全有效的结直肠癌化学预防方法需要了解有该疾病风险的实际患者早期结直肠肿瘤发生的性质，并在人体临床试验中测试新的机械有效的化学预防剂。很少有研究中心拥有成功完成癌症化学预防试验所需的经验丰富的研究人员、资源和支持性基础设施。因此，非常需要培训新的研究人员来进行这项重要的研究。 Monica Bertagnolli 博士是结直肠癌 (CRC) 预防领域经验丰富的转化研究员。她是最近完成的塞来昔布腺瘤预防 (APC) 试验的首席研究员，该试验是一项随机安慰剂对照研究，对 2000 多名 CRC 高危患者进行了研究。她还领导一个实验室，研究恶变前腺瘤的生物学和化学预防化合物的组织特异性作用。这项设立研究者职业发展奖的提案概述了 Bertagnolli 博士的一项计划，即在未来 5 年中花费大量时间指导初级教员进行癌症预防研究。她将利用 APC 试验的大量临床数据和组织资源，为顾问提供必要的原材料，以进行 CRC 发展和化学预防药物反应中可改变因素的研究。在达纳法伯-哈佛癌症中心高级研究人员和外部顾问的协助下，她还建立了一个多学科论坛，用于展示、讨论和批评正在进行的胃肠道癌症预防工作。以优化教育潜力的方式进行高质量的转化研究非常耗时，而 Bertagnolli 博士是少数能够成功完成这项任务的人之一。该奖项提供的支持将使 Bertagnolli 博士能够利用 APC 试验资源完成关键研究项目，从而促进初级教师成长为癌症预防领域的独立研究人员。